User menu

Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?

Bibliographic reference Houssiau, Frédéric ; Doria, Andrea. Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?. In: Annals of the Rheumatic Diseases, Vol. 75, no. 2, p. 321-322 (2016)
Permanent URL http://hdl.handle.net/2078.1/169054
  1. Wofsy David, Hillson Jan L., Diamond Betty, Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials : Outcome Measures for Lupus Nephritis, 10.1002/art.37940
  2. Wallace Daniel J., Stohl William, Furie Richard A., Lisse Jeffrey R., McKay James D., Merrill Joan T., Petri Michelle A., Ginzler Ellen M., Chatham W. Winn, McCune W. Joseph, Fernandez Vivian, Chevrier Marc R., Zhong Z. John, Freimuth William W., A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus, 10.1002/art.24699
  3. Merrill J T, van Vollenhoven R F, Buyon J P, Furie R A, Stohl W, Morgan-Cox M, Dickson C, Anderson P W, Lee C, Berclaz P-Y, Dörner T, Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, 10.1136/annrheumdis-2015-207654
  4. Isenberg D A, Petri M, Kalunian K, Tanaka Y, Urowitz M B, Hoffman R W, Morgan-Cox M, Iikuni N, Silk M, Wallace D J, Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, 10.1136/annrheumdis-2015-207653
  5. Merrill Joan T., Ginzler Ellen M., Wallace Daniel J., McKay James D., Lisse Jeffrey R., Aranow Cynthia, Wellborne Frank R., Burnette Michael, Condemi John, Zhong Z. John, Pineda Lilia, Klein Jerry, Freimuth William W., , Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus, 10.1002/art.34564
  6. van Vollenhoven Ronald F, Petri Michelle A, Cervera Ricard, Roth David A, Ji Beulah N, Kleoudis Christi S, Zhong Z John, Freimuth William, Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response, 10.1136/annrheumdis-2011-200937
  7. Furie Richard, Petri Michelle, Zamani Omid, Cervera Ricard, Wallace Daniel J., Tegzová Dana, Sanchez-Guerrero Jorge, Schwarting Andreas, Merrill Joan T., Chatham W. Winn, Stohl William, Ginzler Ellen M., Hough Douglas R., Zhong Z. John, Freimuth William, van Vollenhoven Ronald F., , A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, 10.1002/art.30613
  8. Navarra Sandra V, Guzmán Renato M, Gallacher Alberto E, Hall Stephen, Levy Roger A, Jimenez Renato E, Li Edmund K-M, Thomas Mathew, Kim Ho-Youn, León Manuel G, Tanasescu Coman, Nasonov Eugeny, Lan Joung-Liang, Pineda Lilia, Zhong Z John, Freimuth William, Petri Michelle A, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(10)61354-2
  9. Cheema Gurtej S., Roschke Viktor, Hilbert David M., Stohl William, Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases, 10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s
  10. Mackay Fabienne, Woodcock Stephen A., Lawton Pornsri, Ambrose Christine, Baetscher Manfred, Schneider Pascal, Tschopp Jurg, Browning Jeffrey L., Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations, 10.1084/jem.190.11.1697
  11. Schneider Pascal, The role of APRIL and BAFF in lymphocyte activation, 10.1016/j.coi.2005.04.005